IP Library Granted Patent US 9,040,504
Granted Patent B2
US 9,040,504 · App. 14/152,916 · Granted May 26, 2015

Beta-lactamase inhibitors

Inventors: Christopher J. Burns (Malvern, PA); Denis Daigle (Havre de Grace, MD); Bin Liu (Dayton, NJ); Daniel McGarry (Exton, PA); Daniel C. Pevear (Downingtown, PA); Robert E. Lee Trout (Bechtelsville, PA); Randy W. Jackson (Livingston, MT)
Assignee: VENATORX PHARMACEUTICALS, INC.
C07F5/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,504
App. No.
14/152,916
Granted
May 26, 2015
Kind
B2
Abstract

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Claims (50)

1. A compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt, polymorph, solvate, N-oxide, or isomer thereof:

wherein:

M is a bond, —O—, —S—, —S(O)—, SO 2 —, or —N(R 4 )—;

m is 0, 1, or 2;

n is 0, 1, 2, or 3;

provided that

when n is 0, then M is a bond;

p is 2;

X 1 and X 2 are independently selected from —OH, —OR 8 , or F;

Z is >C═O, >C═S, or >SO 2 ;

ArA is an optionally substituted aromatic or heteroaromatic ring system;

each Y is selected from the group consisting of

—NR 4 R 5 , —NR 4 C(═NR 5 )NR 4 R 5 , —C(═NR 4 )NR 4 R 5 , —N(R 4 )C(═NR 5 )R 6 , —(CR 6 R 7 ) v NR 4 R 5 , —(CR 6 R 7 ) v N(R 4 )C(═NR 5 )NR 4 R 5 , —NR 4 (CR 6 R 7 ) v NR 4 R 5 , —NR 4 (CR 6 R 7 ) v OR 10 , —(CR 6 R 7 ) v NR 4 (CR 6 R 7 ) v NR 4 R 5 , NR 5 C(═NR 5 )NR 4 (CR 6 R 7 ) v NR 4 R 5 , —NR 4 (CR 6 R 7 ) v N(R 4 )C(═NR 5 )NR 4 R 5 , —NR 5 C(O)CR 6 (NR 4 R 5 )(CR 6 R 7 ) v NR 4 R 5 , —(CR 6 R 7 ) v C(═NR 5 )NR 4 R 5 , —(CR 6 R 7 ) v N(R 4 )C(O)(CR 6 R 7 ) v NR 4 R 5 , —C(═NR 4 )NR 4 C(O)R 6 , —NR 4 (CR 6 R 7 ) v Heteroaryl, and —O(CR 6 R 7 ) v NR 4 R 5 ;

v is 1-4;

or two Ys taken together with the carbon atoms to which they are attached form an optionally substituted carbocycle or an optionally substituted heterocycle;

R a , R b , and R c are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OH, —OR 10 , —NR 4 R 5 , and —SR 10 ;

R 1 and R 2 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, —OH, —OR 10 , —SR 10 , and —NR 4 R 5 ,

or R 1 and R 2 taken together form an oxo, oxime, or an optionally substituted carbocycle or optionally substituted heterocycle with the carbon to which they are attached;

R 3 is hydrogen, or optionally substituted C 1 -C 6 alkyl;

R d , R 4 and R 5 are independently selected from the group consisting of hydrogen, —OH, —CN, optionally substituted C 1 -C 6 alkyl, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, optionally substituted aminoalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, (poly-ethylene-glycol)-ethyl, and an optionally substituted saccharide;

or R 4 and R 5 taken together form an optionally substituted heterocycle with the nitrogen to which they are attached;

R 6 and R 7 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, optionally substituted C 3 -C 6 cycloalkyl, —OH, —OR 10 , —SR 10 , —NR 4 R 5 , —NR 4 C(O)R 5 , —C(O)NR 4 R 5 , —NR 4 SO 2 R 5 , optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

or R 6 and R 7 taken together form an oxo, oxime, or an optionally substituted carbocycle or an optionally substituted heterocycle with the carbon to which they are attached;

R 8 is optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, or a pharmaceutically acceptable boronate ester group;

R 10 is optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 6 cycloalkyl.

2. The compound of claim 1 , wherein R a , R b , and R c are hydrogen.

3. The compound of claim 1 , wherein R 3 is hydrogen.

4. The compound of claim 1 , wherein X 1 and X 2 are —OH.

5. The compound of claim 1 , wherein R d is hydrogen or C 1 -C 4 -alkyl.

6. The compound of claim 1 , wherein Z is >C═O.

7. The compound of claim 1 , wherein:

M is —O—, —S—, —SO 2 —, or —N(R 4 )—;

m is 0 or 1; and

n is 1 or 2.

8. The compound of claim 1 , wherein:

M is a bond; and

m and n are 0.

9. The compound of claim 1 , wherein:

M is a bond; and

m or n are 1.

10. The compound of claim 1 , wherein ArA is selected from the group consisting of benzene, pyridine, pyrimidine, thiophene, thiazole, triazole, indole, benzimidazole, azaindole, thienopyrazole, quinoline, quinazoline, and quinoxaline.

11. The compound of claim 1 , wherein two Y groups taken together with the carbon atoms to which they are attached form an optionally substituted carbocycle or an optionally substituted heterocycle.

12. The compound of claim 11 , wherein two Y groups, together with the carbon atoms to which they are attached form a pyrrolidine ring.

13. The compound of claim 1 , wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl.

14. The compound of claim 1 , wherein R 6 and R 7 are independently hydrogen, fluoro, or optionally substituted C 1 -C 6 alkyl.

15. The compound of claim 1 , wherein the compound is selected from the group represented by the following structures:

or a pharmaceutically acceptable salt, solvate, polymorph, N-oxide, or isomer thereof, wherein the compound is present in a closed, cyclic form according to Formula I and as shown in the structures above, an open, acyclic form according to Formula Ia, or mixtures thereof.

16. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, polymorph, solvate, N-oxide, or isomer thereof, and a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 , further comprising a beta-lactam antibiotic.

18. A method of treating a bacterial infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 16 , optionally in combination with a beta-lactam antibiotic.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 14, 2022
From: VENATORX PHARMACEUTICALS INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061933/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: BURNS, CHRISTOPHER J.; DAIGLE, DENIS; LIU, BIN; MCGARRY, DANIEL; PEVEAR, DANIEL C.; TROUT, ROBERT E. LEE; JACKSON, RANDY W.
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 032402/0291 →
Continuity (3)
Provisional Application 61751161 · Jan 10, 2013
Provisional Application 61783261 · Mar 14, 2013
Related Publication 20140194386A1 · Jul 10, 2014